Announcements 2010

  The turmoil created in the Greek pharmaceutical market since the beginning of the year has seriously affected the turnover of pharmaceutical companies. The anticipation of price changes announced by the government at the beginning of the year and implemented consecutively in June and September, led...

  In the context of the ASE regulations and under the 3/347/12.07.05 Board Resolution of Hellenic Capital Market Commission, Lavipharm advises that Mr. Ioannis Alexiades assumes the responsibility of Internal Auditor replacing Mr. Georgios Gemelos....

  During the first semester of 2010, turmoil was created in the Greek pharmaceutical market, in anticipation of price reductions which were announced by the government at the beginning of the year but were implemented early June. Although, according to IMS data, sales of medicines from...

The turmoil created in the pharmaceuticals' market during the first quarter of 2010 -which continues until today- has significantly affected Lavipharm's Financials. In anticipation of the decrease in drug prices, as expected since the beginning of the year, sales have dropped drastically, due to warehouses’...

Consolidated Turnover posted an increase of 5%, reaching Euro 249.8 million compared to Euro 238.0 million during 2008. International Sales have increased by 17%, accounting for 11% of Total Sales. Gross Profit reached Euro 39.5 million from Euro 37.4 million in the last period (+5.6%)....